SCHEMBL24253408

SCHEMBL24253408

CC(C)c1cc2ncsc2cc1O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
KDM4E B2RXH2 1/20 0.38
HKDC1 Q2TB90 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
TRPA1 O75762 1/20 0.36
CHRM1 P11229 1/20 0.36
SLC6A2 P23975 1/20 0.36
ADRA1A P35348 1/20 0.36
HTR2B P41595 1/20 0.36
ALDH1A1 P00352 1/20 0.34
HSD17B10 Q99714 1/20 0.34
TAS1R3 Q7RTX0 1/20 0.34
TAS1R1 Q7RTX1 1/20 0.34
DYRK1A Q13627 1/20 0.33
GABRA1 P14867 2/20 0.32
GABRB2 P47870 2/20 0.32
CA1 P00915 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24253405 0.93 LMNA (0.38) LMNANPC1RAB9AKDM4EHKDC1
SCHEMBL15912333 0.85 ALDH1A1 (0.39) NPC1RAB9AKDM4EHKDC1TDP1
SCHEMBL8980138 0.82 NPC1 (0.43) NPC1RAB9AKDM4EHKDC1TDP1
SCHEMBL24932464 0.80 ALDH1A1 (0.35) LMNANPC1RAB9AKDM4EHKDC1
SCHEMBL25091587 0.80 NPC1 (0.33) NPC1RAB9A
SCHEMBL6298458 0.79 ALDH1A1 (0.34) NPC1RAB9AKDM4EHKDC1TDP1
SCHEMBL24984324 0.79 TGFBR1 (0.35) NPC1RAB9AKDM4EHKDC1TDP1
SCHEMBL6031739 0.78 NPC1 (0.46) LMNANPC1RAB9AKDM4EHKDC1
SCHEMBL24611377 0.77 ALDH1A1 (0.33) NPC1RAB9AKDM4EHKDC1TDP1
SCHEMBL25569778 0.76 ALDH1A1 (0.35) NPC1RAB9AKDM4EHKDC1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230227474-A1 COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING SKYHAWK THERAPEUTICS, INC. (US) 2023-07-20 US disclosed
US-20230069804-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-03-02 US disclosed
US-20230054781-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-02-23 US disclosed
US-20230027684-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-01-26 US disclosed
US-20230020922-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-01-19 US disclosed
US-20230008867-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-01-12 US disclosed
US-20230009712-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-01-12 US disclosed
US-20220048890-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220048890-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 LMNA 246/4885NPC1 2066/4885RAB9A 2924/4885
US-20230008867-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SNRPA1 LMNA 218/4885NPC1 2258/4885RAB9A 3071/4885
US-20230020922-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SNRPA1 LMNA 218/4885NPC1 2258/4885RAB9A 3071/4885
US-20230027684-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 LMNA 246/4885NPC1 2066/4885RAB9A 2924/4885
US-20230009712-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 LMNA 246/4885NPC1 2066/4885RAB9A 2924/4885
US-20230227474-A1 COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING RBM17, SF3B1, SF3B5 LMNA 301/4885NPC1 1934/4885RAB9A 1892/4885
US-20230069804-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 LMNA 246/4885NPC1 2066/4885RAB9A 2924/4885
US-20230054781-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 LMNA 246/4885NPC1 2066/4885RAB9A 2924/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.